Year: 2024

Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, announced today the appointment of Alan Sandler, M.D., as Chief Medical Officer. “Dr. Sandler’s breadth of experience and demonstrated leadership capabilities across oncology and drug development, as well as his in-depth knowledge of ALX Oncology while he was a member of our Board, will be instrumental in helping us achieve our near- and longer-term objectives,” said Jason Lettmann, Chief Executive Officer at ALX Oncology. “He is the ideal...

CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Combo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET). A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page. Institutional investors interested in meeting with management during the conference may reach out to their Jefferies representatives. About Solid BiosciencesSolid Biosciences is a precision...

Topline Real-World Evidence (RWE) Comparability and Outcomes Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected by Year-End 2024; Biologics License Application (BLA) Submission Targeted for First Half 2025 Ongoing Enrollment in Phase 3 ARCHER II Trial for ANX007 in Geographic Atrophy (GA); Topline Data Expected Second Half 2026 Proof-of-Concept Study with First-in-Kind Oral C1s Inhibitor ANX1502 Transitioned to an Enhanced Tablet Formulation; Data in Cold Agglutinin Disease (CAD) Expected in First Quarter 2025 Bolstered Commercial, Medical Affairs and Health Economics Senior Leadership in Preparation for Potential ANX005 Commercialization Robust Balance Sheet with Cash, Cash Equivalents, and Short-term Investments of Approximately $340 Million as of September 30, 2024, and Anticipated Runway into Second Half 2026 BRISBANE, Calif.,...

LIMASSOL, Cyprus, Nov. 14, 2024 (GLOBE NEWSWIRE) — GDEV Inc. (NASDAQ: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”) released its unaudited financial and operational results for the third quarter and first nine months ended September 30, 2024. GDEV CEO, Andrey Fadeev noted: ”In Q3, despite industry pressure, we delivered sequential revenue growth. We also kept executing our strategy and moved forward with the transformation of our core products. The updates are rolling across our main franchises to elevate the game experience, adding new modern features to what players already love. We are not after quick wins – it’s about innovating in a way that sets us up for lasting impact. We are pleased to have established an at-the-market offering (“the ATM”) in September as an important step towards...

Nes-Ziona, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) —  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the completion of the dosing and initial follow-up period for the first patient in its Phase I clinical trial evaluating the safety, tolerability and potential therapeutic effect of Allocetra™ following injection into an affected joint in patients with psoriatic arthritis. No safety concerns were recorded following the dosing of the first patient. The trial currently plans to recruit six patients who have insufficiently responded to conventional therapies for psoriatic arthritis. The primary safety endpoint will measure the frequency and severity of adverse events and serious adverse events, and secondary endpoints will include assessments...

Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted extension until December 9 to regain compliance with Nasdaq listing requirements for market value of securities SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. The company will not host a conference call. “We’ve made much faster progress than anticipated developing a smaller BioJet device that is highly desired by pharma companies,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. “We recently presented initial animal data on our 00-size, clinical BioJet device. We...

COLUMBUS, Ohio, Nov. 14, 2024 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding,” “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today announced that David Duvall, President and CEO, and John Zimmer, EVP and CFO, will participate in the 16th Annual Southwest IDEAS Conference in Dallas on November 21, 2024. The Company will host one-on-one investor meetings throughout the day, and their presentation time is 4:10-4:45 PM CT on November 21st. The presentation will be webcast live and can be accessed through the investor relations section of Core Molding Technologies at https://coremt.com/investor-relations/events-presentations....

VANCOUVER, British Columbia, Nov. 14, 2024 (GLOBE NEWSWIRE) — Boba Mint Holdings Ltd. (CSE: TNJ), a pioneering blockchain gaming company, is proud to announce significant milestones in the growth and development of its flagship blockchain game, Tanjea. Built on the robust Ethereum network, Tanjea offers players a unique play-to-earn experience where they can collect, trade, and use NFT characters, earning rewards in the form of the $TNJ token. Since the last user download update in May, Tanjea has experienced remarkable growth, with total game downloads now surpassing 409,670, and over 24,000 monthly active users on the Android platform alone. This rapid increase in user engagement underscores the platform’s rising popularity and the growing interest in blockchain-based gaming. Following this surge in user engagement, Boba Mint...

Study results add to the growing body of evidence differentiating sotagliflozin within SGLT inhibitor class THE WOODLANDS, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from four studies of sotagliflozin will be delivered during the American Heart Association’s (AHA) Sessions 2024 being held November 16-18 at McCormick Place Convention Center in Chicago, Illinois. One of those studies, a secondary analysis of data from the Phase 3 SCORED clinical trial, examined the association of heart failure stage with cardiovascular disease and kidney events. Researchers in the study observed that sotagliflozin had similar relative benefits for all endpoints, irrespective of heart failure stage, with a corresponding increase in absolute benefits at earlier stages. Details of the...

Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported selected financial results for the third quarter ended September 30, 2024. “OvaWatch® product volume, which we believe is the most important indicator of future growth, grew an impressive 27% in the third quarter when compared to last year. This was achieved in spite of severe weather...